A high expression of α-SMA is significantly associated with advanced clinical stages of the disease and a lower degree of tumour differentiation (x2, p ≤ 0.05); notably, 76% of patients in stages III–IV or who present undifferentiated tumours have a high α-SMA expression degree. Here, ACTA1 is linked to neoplasm.